Kamada (KMDA) Retained Earnings (2012 - 2026)
Kamada's (KMDA) quarterly Retained Earnings came in at $268.4 million in Q2 2026, little changed on a YoY basis from $268.2 million in Q2 2025, and little changed quarter-over-quarter from $268.4 million in Q1 2026.
Analysis
Kamada (KMDA) Retained Earnings (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Retained Earnings for 15 consecutive years, with $268.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Retained Earnings changed 0.06% year-over-year to $268.4 million; the trailing twelve-month figure through Jun 2026 stood at $268.4 million (changed 0.06% YoY), and the FY2025 full-year result was $268.3 million, up 0.51% from the prior year.
- Retained Earnings held at $268.4 million in Q2 2026 per KMDA's latest filing, from $268.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $268.4 million in Q2 2026 and bottomed at -$45.3 million in Q3 2023.
- Historically, Retained Earnings has averaged $231.1 million across 5 years, with a median of $266.2 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings sank 121.52% in 2023, then jumped 689.04% in 2024.
- Over 5 years, Retained Earnings stood at $210.5 million in 2022, then rose by 26.3% to $265.8 million in 2023, then grew by 0.41% to $266.9 million in 2024, then advanced by 0.51% to $268.3 million in 2025, then gained by 0.05% to $268.4 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $268.4 million, $268.4 million, and $268.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 5.13 Bn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 268.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 268.40 Mn |
| Mar 31, 2026 | 268.36 Mn |
| Dec 31, 2025 | 268.28 Mn |
| Sep 30, 2025 | 268.22 Mn |
| Jun 30, 2025 | 268.24 Mn |
| Mar 31, 2025 | 268.16 Mn |
| Dec 31, 2024 | 266.93 Mn |
| Sep 30, 2024 | 266.59 Mn |
| Jun 30, 2024 | 266.31 Mn |
| Mar 31, 2024 | 266.18 Mn |
| Dec 31, 2023 | 265.85 Mn |
| Sep 30, 2023 | -45.26 Mn |
| Jun 30, 2023 | 210.73 Mn |
| Mar 31, 2023 | 210.67 Mn |
| Dec 31, 2022 | 210.50 Mn |
| Sep 30, 2022 | 210.36 Mn |
| Jun 30, 2022 | 210.32 Mn |
| Mar 31, 2022 | 210.27 Mn |
| Dec 31, 2021 | 210.20 Mn |
| Sep 30, 2021 | 210.01 Mn |